Paying the piper for pharmacoeconomic studies

Medical Decision Making

Volumn 18, Issue 2 SUPPL., 1998, Pages

  Neumann, Peter J ^a  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; FINANCE; MANAGED CARE; PEER REVIEW; PHARMACOECONOMICS; REVIEW;

CONFLICT OF INTEREST; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HUMANS; RESEARCH; UNITED STATES; UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES;

EID: 0031948222     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989x98018002s05     Document Type: Review

References (34)

1. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practice. N Engl J Med. 1977;296:716-21.
2. Evans R. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med. 1995;123:59-60.
3. Fuchs VR, Garber AM. The new technology assessment. N Engl J Med. 1990;323:673-7.
4. Integrated Pharmaceutical Services and Foundation Health Corporation. Guidelines for formulary submissions. Rancho Cordova, CA: Integrated Pharmaceutical Services and Foundation Health Corporation, 1996.
5. Regence Washington Health Pharmacy Service. Guidelines for Submission of Clinical and Economic Data Supporting Formulary Considerations, Version 1.2. Regence Washington Health, University of Washington, Seattle, WA, September 1997.
6. Lax J, Moench E. Pharmacoeconomics and Managed Care: Understanding the Issues, Concerns, and the Environment. Presentation at the Food and Drug Administration Hearing "Pharmaceutical Marketing and Information Exchange in Managed Care Environments," Silver Spring, MD, October 19, 1995.
7. Zellmer W. Comments of the American Society of Health-System Pharmacists. Presentation at the Food and Drug Administration Hearing "Pharmaceutical Marketing and Information Exchange in Managed Care Environments," Silver Spring, MD, October 19, 1995.
8. Luce BR, Lyles AC, Rentz AM. The view from managed care pharmacy. Health Aff. 1996;4:168-76.
9. Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost-containment, and the use of cost-effectiveness analysis. Soc Sci Med. 1997;45(4):525-33.
10. Stephenson J. Medical technology watchdog plays unique role in quality assessment. JAMA. 1995;274:999-1001.
11. Paltiel AD, Neumann PJ. Why training is the key to successful guideline implementation. Pharmacoeconomics, 1997;12:297-302.
12. Powe, et al. Awareness of providers' use of new medical technology among private health care plans in the United States. Int J Technol Assess Health Care. 1996;12:367-76.
13. Garrison LP. Pharmacoeconomic Evaluations: A Pharmaceutical Companys Perspective. Presentation at the Annual Meeting of the Association of Pharmacoeconomics and Out-comes Research, May 13, 1997.
14. Neumann PJ. Government uses of cost-effectiveness information on drugs. In: Calfee J. (ed). Paper presented at a conference, Policy Issues in Pharmaceutical Cost-Effectiveness Research. Washington, DC: American Enterprise Institute, November 1996.
15. Neumann PJ, Zinner DE, Paltiel AD. The FDA's regulation of cost-effectiveness claims. Health Aff. Fall 1996:54-71.
16. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Intern Med. 1992;116(3):238-44.
17. Neumann PJ, Zinner DE, Wright JC. Are methods for estimating QALYs in cost-effectiveness analyses improving? Med Decis Making. 1997;17:402-8.
18. Kassirer J, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med. 1994;331:669-70.
19. BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to BMJ. BMJ. 1996;313:275-83.
20. Drummond JF, Richardson WS, O'Brien BJ, Levine M, Heyland D. Users' guide to the medical literature: how to use an article on economic analysis of clinical practice. Part A. JAMA. 1997;277:1552-7.
21. O'Brien BJ, Heyland D, Richardson WS, Levine M, Drummond JF. Users' guide to the medical literature: how to use an article on economic analysis of clinical practice. Part B. JAMA. 1997;277:1802-6.
22. Elstein A. MDM policy regarding financial support of authors. Med Decis Making. 1997;17:497-8.
23. Schulman K, Sulmasy DP, Roney D. Ethics, economics, and the publication policies of major medical journals. JAMA. 1994;272:154-6.
24. Jefferson T, Demicheli V. Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practices. Health Econ. 1995;4:383-8.
25. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: a report on principles. Ann Intern Med. 1995;123:61-70.
26. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253-8.
27. Dong BJ, Hauck WW, Gambertoglio JG, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA. 1997;277:1205-13.
28. Rennie D. Thyroid storm (editorial). JAMA. 1997;277:1238-43.
29. King R. Bitter pill: how a drug company paid for university study, then undermined it. Wall Street Journal. April 25, 1996:1.
30. O'Brien B. St. Joseph's Hospital, Hamilton, Ontario. Personal communication, November 1997.
31. Neumann PJ, Zinner DE. Evaluating and regulating pharmacoeconomic information in the private sector. Drug Information Journal, in press, 1998.
32. Reinhardt UE. Making economic evaluations respectable. Soc Sci Med. 1997;45:555-62.
33. Food and Drug Administration, Division of Drug Marketing, Advertising, and Communication. Principles for the Review of Pharmacoeconomic Promotion. Draft guidelines, 1995.
34. United States Congress. Prescription Drug User Fee Act (US House Bill 1141 and US Senate Bill 830), Washington, DC, 1997.